fashion -WSS

fashion

author：explore 2025-09-29 11:20:19 - browse：11572

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： STAT Virtual Event: Putting AI to the Test

WSS

Food as medicine: Medically tailored meals may get standardized

Covid vaccine financial winners and losers, from Pfizer to Novavax

Abortion pill case raises question: who can sue the FDA?

Why the world’s most expensive drug might be worth the price

How AI helped researchers track recovery from depression

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Wikipedia

fashion

knowledge

Alkermes shareholders re

Oprah kicked off a national conversation on obesity. Let's have it

Bright Health sells Medicare Advantage business to Molina

Biotech stock slump in 2023: awaiting the turnaround

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Senators: Long

United colonoscopy coverage change 'may cost lives,' doctors say

Food as medicine: Medically tailored meals may get standardized

After affirmative action ruling, medical educators look to 'holistic review'

Will generative AI in health care meet the fate of IBM's Dr. Watson?

leisure time

States should stop sabotaging methadone treatment reform

Medical student insurance fails on mental health care coverage

EpiPen alternative approval delay highlights citizen petition issue

Donor acceptance rates hint at racial, gender bias in heart transplants: study

STAT Virtual Event: Putting AI to the Test

Readout LOUD podcast: mifepristone case, GLP

focus

knowledge

focus

hotspot